Celgene Corp. v. Peter, Appeal Nos. 2018-1167, -1168, -1169 (Fed. Cir. July 30, 2019)
By John Isacson
Celgene owned two patents that pertained to methods of safely distributing potentially hazardous drugs. The patents were challenged in an inter partes review (IPR) as obvious over the prior art. The Board determined that the patents were obvious.